Sun Pharmaceutical Industries Limited vs Cipla Limited
An objective side-by-side of SUNPHARMA and CIPLA, both in Pharmaceuticals - Indian - Bulk Drugs & Formln: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: SUNPHARMA Jun 2026 · CIPLA Jun 2026
At a glance
- Sun Pharmaceutical Industries Limited is the larger company by market value, about 4.0 times the size of Cipla Limited.
- On trailing earnings, Cipla Limited trades at the lower P/E (33.4 against 37.0).
- Sun Pharmaceutical Industries Limited earns the higher return on equity (14.5% against 9.7%).
- Over three years Sun Pharmaceutical Industries Limited has grown profits faster (13% a year against 10%).
- Over the past year the share prices returned +16.7% (SUNPHARMA) and -10.5% (CIPLA).
| Metric | Sun Pharmaceutical SUNPHARMA |
Cipla CIPLA |
|---|---|---|
| Size and price | ||
| Market cap | ₹448,412 Cr | ₹111,977 Cr |
| Share price | ₹1,869 | ₹1,386 |
| Valuation | ||
| P/E | 37.05 | 33.36 |
| P/B | 5.37 | 3.25 |
| EV/EBITDA | 25.38 | 21.26 |
| PEG | 2.85 | 3.34 |
| Dividend yield | 0.9% | 0.9% |
| Profitability | ||
| ROE | 14.5% | 9.7% |
| ROCE | 21.0% | 15.0% |
| Operating margin | 29.8% | 18.7% |
| Sales (TTM) | ₹59,911 Cr | ₹28,324 Cr |
| Net profit (TTM) | ₹12,104 Cr | ₹3,356 Cr |
| Growth | ||
| Latest quarter sales YoY | +10.5% | +2.3% |
| Latest quarter profit YoY | +27.0% | -39.2% |
| Sales CAGR 3Y | +10.0% | +7.0% |
| Profit CAGR 3Y | +13.0% | +10.0% |
| Sales CAGR 5Y | +12.0% | +8.0% |
| Profit CAGR 5Y | +17.0% | +10.0% |
| Financial strength | ||
| Debt/Equity | 0.06 | 0.02 |
| Interest cover | 43.64 | 86.10 |
| Ownership | ||
| Promoter holding | 54.5% | 29.2% |
| Promoter change (4 qtrs) | +0.00 pp | +0.02 pp |
| Price performance | ||
| Return 1M | -1.84% | -3.61% |
| Return 3M | +0.32% | -2.09% |
| Return 1Y | +16.66% | -10.48% |
| Return YTD | +8.68% | -8.28% |
| Technical condition | ||
| Technical score | 35 | 37 |
| RS rating (1-99) | 60.00 | 47.00 |
| % vs 200-DMA | +3.42% | -0.07% |
| RSI (14) | 45.40 | 45.81 |
| % from 52-week high | -8.70% | -17.15% |
